证券代码：301201 证券简称：诚达药业 公告编号：2023-046 诚达药业股份有限公司 关于部分首次公开发行前已发行股份上市流通的 提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次解除限售的股份为诚达药业股份有限公司（以下简称"公司"或"发 行人"）首次公开发行前已发行的部分股份。 2、本次解除限售股东户数共计 1 户，解除限售股份的数量为 3,200,000 股， 占公司发行后总股本的 2.07%。 公司首次公开发行前总股本为 72,522,105 股，首次公开发行后总股本为 96,696,140 股。其中：无限售条件流通股的股票数量为 22,018,689 股，占发行 后总股本的比例为 22.77%，有限售条件流通股/非流通股的股票数量为 74,677,451 股，占发行后总股本的比例为 77.23%。 （二）首次公开发行股份上市后股份变动情况 2022 年 7 月 20 日，公司首次公开发行网下配售限售股上市流通，股份数量 为 1,247,381 股，占发行后总股本的 1.29%，具体情况详见公司 2022 年 7 ...

Financial Performance - The company's operating revenue for Q3 2023 was ¥93,670,049.75, representing a 5.94% increase year-over-year[5]. - Net profit attributable to shareholders for Q3 2023 was ¥31,832,247.81, an increase of 18.09% compared to the same period last year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥19,913,982.14, up 30.78% year-over-year[5]. - The net profit for Q3 2023 was CNY 61,275,166.69, a decrease of 33.5% compared to CNY 91,990,029.78 in Q3 2022[21]. - Operating profit for the period was CNY 72,429,682.25, down from CNY 109,884,155.18 in the same period last year, reflecting a decline of 34.1%[21]. - The total comprehensive income attributable to the parent company was CNY 61,184,204.86, down from CNY 92,047,145.90 in the same quarter last year, a decrease of 33.5%[21]. Cash Flow and Liquidity - The net cash flow from operating activities for the first nine months of 2023 was ¥146,431,354.93, a significant increase of 1,030.26% compared to the same period last year[10]. - Cash flow from operating activities generated a net amount of CNY 146,431,354.93, significantly up from CNY 12,955,580.95 in the previous year[22]. - Cash flow from investing activities showed a net inflow of CNY 689,223,998.96, a recovery from a net outflow of CNY 1,102,244,307.66 in the prior year[23]. - Total cash and cash equivalents at the end of the period reached CNY 1,413,005,628.92, compared to CNY 441,903,213.50 at the end of Q3 2022, marking an increase of 219.5%[23]. - The company's cash and cash equivalents increased by 133.77% to ¥1,413,005,628.92 due to the redemption of financial assets during the reporting period[9]. Assets and Liabilities - Total assets as of September 30, 2023, were ¥2,391,446,657.00, reflecting a 3.00% increase from the end of the previous year[5]. - The company's total liabilities increased to CNY 142,537,829.43 from CNY 105,811,942.95, indicating a rise in financial obligations[18]. - The equity attributable to shareholders rose to CNY 2,247,141,388.38 from CNY 2,214,407,215.52, demonstrating a strengthening of shareholder value[19]. - Inventory levels increased to CNY 164,857,644.32 from CNY 156,426,891.52, suggesting potential growth in sales or production[17]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,838[11]. - The largest shareholder, Ge Jianli, holds 27.17% of the shares, totaling 42,031,360 shares[11]. - Huang Honglin, the second-largest shareholder, owns 12.62% of the shares, amounting to 19,528,000 shares[11]. - The top ten shareholders collectively hold significant stakes, with the third-largest being Shenzhen Shengtai Investment Management Co., holding 11.24% or 17,391,840 shares[11]. - The total number of restricted shares at the end of the period is 70,720,000, with 29,230,070 shares released from restrictions during the period[15]. Investment and Expenses - The company's investment income for the first nine months of 2023 was ¥29,434,778.21, a 219.83% increase year-over-year[9]. - Research and development expenses increased to CNY 15,895,510.73, up from CNY 14,626,261.48, indicating a focus on innovation[20]. - The company reported a net investment income of CNY 29,434,778.21, a significant increase from CNY 9,203,163.19, highlighting successful investment strategies[20]. Other Information - The company completed a board election on May 16, 2023, with a former supervisor no longer serving[15]. - The company plans to lift restrictions on shares held by Shenzhen Jiuheng Investment Consulting Co., totaling 3,200,000 shares, on November 17, 2023[15]. - The company did not report any net profit from the merged entity during the current or previous periods[22]. - The company has not undergone an audit for the Q3 report[24].

证券代码：301201 证券简称：诚达药业 公告编号：2023-044 诚达药业股份有限公司 关于完成工商变更登记的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、工商变更登记情况 诚达药业股份有限公司（以下简称"公司"）于 2023 年 4 月 20 日召开的第 四届董事会第十五次会议、2023 年 5 月 16 日召开的 2022 年年度股东大会审议 通过了《关于修订<公司章程>的议案》。具体内容详见公司于 2023 年 4 月 24 日 在巨潮资讯网披露的《关于修订<公司章程>的公告》（公告编号：2023-017）。 公司于 2023 年 8 月 21 日召开的第五届董事会第三次会议、2023 年 9 月 7 日召开的 2023 年第二次临时股东大会审议通过了《关于变更公司注册资本、修 订<公司章程>并办理工商变更登记的议案》。具体内容详见公司于 2023 年 8 月 23 日在巨潮资讯网披露的《关于变更公司注册资本、修订<公司章程>并办理工 商变更登记的公告》（公告编号：2023-041）。 公司于近日完成了上述工商变更登记，并取得了浙江省市 ...

证券代码：301201 证券简称：诚达药业 公告编号：2023-043 诚达药业股份有限公司 2023 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会不存在否决议案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、召开时间： （1）现场会议时间：2023 年 9 月 7 日（星期四）下午 14：00 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为 2023 年 9 月 7 日的交易时间，即 9:15-9:25、9:30—11:30 和 13:00—15:00； 通过深圳证券交易所互联网投票的具体时间为：2023 年 9 月 7 日 9:15—15:00。 （一）股东出席的总体情况 通过现场和网络投票的股东 8 人，代表股份 67,599,560 股，占上市公司总 股份的 43.6933％。其中：通过现场投票的股东 4 人，代表股份 67,520,000 股， 占上市公司总股份的 43.6419％；通过网络投票的股东 4 人，代表股份 ...

地址：杭州市萧山区钱江世纪城广孚中心 1301 电话：0571-83685215 传真：0571-83685215 邮编：311200 北京中伦文德（杭州）律师事务所 关于 诚达药业股份有限公司 2023 年第二次临时股东大会的 法律意见书 北京中伦文德（杭州）律师事务所 北京中伦文德（杭州）律师事务所 法律意见书 北京中伦文德（杭州）律师事务所 关于诚达药业股份有限公司 2023 年第二次临时股东大会的 法律意见书 致：诚达药业股份有限公司 北京中伦文德（杭州）律师事务所（以下称"本所"）接受诚达药业股份有限 公司（以下称"公司"）的委托，指派律师出席公司 2023 年第二次临时股东大会 （以下称"本次股东大会"），本所律师根据《中华人民共和国公司法》（以下称 "《公司法》"）、《中华人民共和国证券法》（以下称"《证券法》"）、《上市 公司股东大会规则》（以下简称"《股东大会规则》"）、《深圳证券交易所上市 公司股东大会网络投票实施细则》等法律、法规和规范性法律文件以及《诚达药 业股份有限公司章程》（以下称"《公司章程》"）的规定，就公司本次股东大会 的召集召开程序、出席会议人员的资格、召集人的资格、表决程 ...

光大证券股份有限公司 关于诚达药业股份有限公司 2023 年半年度跟踪报告 | 保荐机构名称：光大证券股份有限公司 | 被保荐公司简称：诚达药业 | | --- | --- | | 保荐代表人姓名：杨科 | 联系电话：021-22169999 | | 保荐代表人姓名：范国祖 | 联系电话：021-22169999 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0 次 | | 2．督导公司建立健全并有效执行规章制度 | | | 的情况 | | | （1）是否督导公司建立健全规章制度（包 括但不限于防止关联方占用公司资源的制 | | | | 是 | | 度、募集资金管理制度、内控制度、内部 | | | 审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 6 次 | | （2）公司募集资金项目进展是否与信息披 | 是 | | 露文件一致 | ...

Financial Performance - ChengDa Pharmaceuticals reported a revenue increase of 15% year-over-year for the first half of 2023, reaching RMB 500 million[19]. - The company's operating revenue for the first half of 2023 was ¥166,587,737.90, a decrease of 23.31% compared to ¥217,228,868.20 in the same period last year[25]. - Net profit attributable to shareholders was ¥29,351,957.05, down 54.91% from ¥65,090,958.64 year-on-year[25]. - Basic and diluted earnings per share decreased by 56.79% to ¥0.3035 from ¥0.7024 in the same period last year[25]. - The gross profit margin for the first half of 2023 was reported at 45%, a slight increase from 42% in the previous year[19]. - The company achieved a total comprehensive income of ¥29,414,513.23 for the first half of 2023, compared to ¥65,057,747.84 in the same period of 2022[171]. - Total operating revenue for the first half of 2023 was CNY 166,364,869.33, down 23.36% from ¥217,228,868.20 in the first half of 2022[173]. - The company reported a net cash flow from operating activities of ¥88,300,602.20, significantly up from ¥35,543,000.80 in the first half of 2022[176]. Research and Development - The company plans to invest RMB 100 million in R&D for new drug development and technology enhancements in the upcoming year[19]. - Research and development expenses increased by 1.57% to CNY 9,700,270.65, with 30 pharmaceutical intermediate projects and 6 raw material projects underway[48]. - The company’s R&D capabilities are supported by multiple high-tech platforms and a focus on innovative chemical synthesis processes, enhancing its competitive edge[40]. - Research and development expenses for the first half of 2023 were CNY 9.70 million, slightly up from CNY 9.55 million in the same period of 2022[170]. - The company is focused on the development of new products, including L-carnitine, and is exploring overseas project expansion[84]. Market Expansion and Strategy - ChengDa Pharmaceuticals has outlined a market expansion strategy targeting Southeast Asia, aiming for a 30% increase in market share by 2025[19]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence[19]. - The company plans to enhance its market expansion strategies and invest in new product development to drive future growth[182]. - The company plans to expand its market presence through new product development and strategic partnerships in the pharmaceutical sector[194]. Financial Management and Investments - The company has a total of CNY 486,943.80 in restricted cash due to acceptance guarantees[60]. - The company has invested CNY 5,119 million in commitment projects, with a cumulative investment of CNY 36,388 million[68]. - The company has a project for the annual production of 155 tons of pharmaceutical intermediates, with an investment of CNY 20,000 million planned by December 2024[68]. - The company has utilized 96,360.72 million yuan of idle raised funds for cash management, with the remaining funds stored in designated accounts[70]. - The company reported a total of 110,816.71 million yuan in raised funds, with 33,200 million yuan allocated for permanent working capital supplementation[70]. Environmental Compliance and Social Responsibility - The company is actively managing its environmental compliance according to various national laws and standards related to pollution control[92]. - The company emphasizes safety production management and has established a comprehensive safety responsibility system to mitigate risks associated with hazardous materials[81]. - The company has initiated charitable activities, including donations to hospitals and support for special needs children, reflecting its commitment to social responsibility[113]. - The company has established an emergency response plan for environmental incidents, which was reviewed by experts and re-registered in August 2021[109]. - There were no administrative penalties related to environmental issues during the reporting period, indicating compliance with environmental regulations[110]. Shareholder Information - The company held its annual general meeting on May 16, 2023, electing a new board of directors and supervisory board[137]. - The total number of shares before the change was 96,696,100, with 100% ownership, and after the change, it remains 96,696,100 shares[142]. - Major shareholder Ge Jianli holds 27.17% of shares, totaling 26,269,600 shares[148]. - The company plans to maintain its current share structure and does not anticipate any significant changes in the near future[145]. - The release of shares from restrictions is expected to enhance liquidity and potentially impact the stock price positively[146]. Operational Efficiency - The company plans to increase production capacity by 41,000 liters with the new workshop expected to start trial production in Q4 2023[49]. - The company has invested in advanced production technologies and information systems to enhance production efficiency and operational effectiveness[41]. - The company aims to improve operational efficiency and reduce costs by 5% in the upcoming quarters[187]. - The company has implemented measures to control energy consumption and improve energy utilization, contributing to cost reduction and enhanced environmental awareness[113].

诚达药业股份有限公司 2023 年半年度募集资金存放与使用情况专项报告 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 | 项目 | | | | 金额（万元） | | | | --- | --- | --- | --- | --- | --- | --- | | 募集资金净额 | | | | 162,144.75 | | | | 本期募集资金置换预先投入募投项目金额（-） | | | | | | | | | | | | | | 8,622.32 | | 本期投入募投项目金额（-） | | | | | 22,646.72 | | | 募集资金到账时未支付的发行费用存入募集资金专 | | | | | | | | 户金额（+） | | | | | | 1,877.75 | | 本期置换已支付发行费用自筹资金的金额（-） | | | | | | | | | | | | | | 1,452.30 | | 本期支付的发行费用（-） | | 425.45 | | | | | | 账户利息收入扣除手续费净额（+） | | | | | | 3,787.71 | | 截止 2022 年 12 月 31 日募集资金专户 ...

证券代码：301201 证券简称：诚达药业 公告编号：2023-040 诚达药业股份有限公司 关于调整公司组织机构的公告 2023 年 8 月 23 日 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 附件：调整后的组织机构图 诚达药业股份有限公司（以下简称"公司"）于 2023 年 8 月 21 日召开第五 届董事会第三次会议，审议通过了《关于调整公司组织机构的议案》，公司根据 经营发展需要，为进一步完善公司的治理结构，提升专业化管理水平和运营效率， 对部分组织机构进行调整与优化，并授权公司经营管理层负责公司组织机构调整 后的具体实施及进一步优化等相关事宜。 本次调整后的公司组织机构图见附件。 特此公告。 诚达药业股份有限公司董事会 ...

| | | 占用方与上市公司 | 上市公司核算的 | 2023 年 | 2023 年半年度 | 2023 年半年 | 2023 年半 | 2023 年半 | 占用形成 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 的关联关系 | 会计科目 | 期初占用 | 占用累计发生金 | 度占用资金的 | 年度偿还累 | 年度期末占 | 原因 | 占用性质 | | | | | | 资金余额 | 额（不含利息） | 利息（如有） | 计发生金额 | 用资金余额 | | | | 控股股东、实际控制人 | - | - | - | - | - | - | - | - | - | - | | 及其附属企业 | - | - | - | - | - | - | - | - | - | - | | 小计 | - | - | - | - | - | - | - | - | - | - | | 前控股股东、实际控制 | - | - | - | - | - | - | - | - | - | - | ...